Invited Faculty
  • Jeffrey R Curtis
    Univ. of Alabama
  • Dr. Jeffrey Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He completed a graduate program in Clinical Informatics at Stanford University and received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics.

    Dr. Curtis holds the Harbert-Ball Endowed Professorship in Rheumatology and Immunology at UAB. His major research emphasis is on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. He also conducts both investigator-initiated and industry-sponsored clinical trials in rheumatoid arthritis (RA) and spondyloarthritis (SpA), including large pragmatic trials. He is the PI of the UAB P30 Informatics Core funded by NIH (NIAMS), focused on digital health and ‘big data’ in musculoskeletal diseases. He is the lead of the UAB Data and Analytic Center (DAC), one of two Coordinating Centers for the ACR’s Rheumatology Informatics System for Effectiveness (RISE), the largest EHR-based rheumatology registry in the world. RISE aggregates and normalizes EHR data from more than 3 million rheumatology patients, with data contributed by more than 1,000 rheumatology providers. He is Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large and linked data sources to study comparative effectiveness questions across multiple chronic diseases. He is the Co-PI of the mobile health-based, PCORI-funded Patient Powered Research Network “ArthritisPower” research registry, focused on RA, psoriasis, psoriatic arthritis, and Spondyloarthritis that has enrolled more than 30,000 patients. In 2022, he co-created the nation’s largest community rheumatology practice-based research network, the Excellence Network in RheumatoloGY (ENRGY), that is optimized for prospective observational and interventional research studies including traditional, platform, and decentralized clinical trials.
    The data sources he routinely uses include national electronic health record, health plan claims (e.g. Medicare, commercial insurance), traditional registry, patient reported outcomes, mobile device, and wearable technologies; he has done numerous projects that link these disparate data sources together. In 2012, he was awarded the Henry Kunkel Young Investigator Award by the American College of Rheumatology (ACR) and was accepted into the American Society for Clinical Investigation (ASCI) in 2016. In 2015, Dr. Curtis was appointed as a member to the FDA Arthritis Advisory Committee, and also the CDC’s ACIP Herpes Zoster Working Group. In 2020, he was appointed lead of the ACR’s COVID Vaccine Clinical Guidance Task Force, and he also serves as a member of the ACR’s 2022 Vaccine Guideline Committee. In addition to vaccine research, Dr. Curtis studies the efficacy, comparative effectiveness, and safety of the medications, devices, and devices used in the care of rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients. In the past, he served on the Core Expert Panel for the ACR’s 2008, 2012, and 2015 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA.

    Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), the American Medical Informatics Association (AMIA), and the American Society of Bone and Mineral Research (ASBMR). He has been on the editorial board for Arthritis & Rheumatology, Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R). According to Google Scholar, he has an H-index of 97 and an i-10 index of 447, and he has coauthored more than 700 peer-reviewed manuscripts, review articles and book chapters.
    Research & Clinical Focus

    Rheumatoid arthritis




    Real World evidence

  • Date Time Room Session Title Lecture Title
    May 17 11:00-11:30 Room Room1 International Symposium 2_Optimal Care for Patients with Rheumatic Diseases: Minimizing Treatment-Related Infectious Complications H. zoster infection in rheumatic disease
    May 17 14:00-14:30 Room Room1 International Symposium 3_Application of Digital Technology in Health Care for Patients with Rheumatic Diseases Digital health strategies to optimize clinical research and care in rheumatology